PGP9.5 promoter methylation is an independent prognostic factor for esophageal squamous cell carcinoma

Cancer Research

Volumn 65, Issue 11, 2005, Pages 4963-4968

  Mandelker, Diana L ^a   Yamashita, Keishi ^a   Tokumaru, Yutaka ^a   Mimori, Koshi ^b   Howard, David L ^a   Tanaka, Yoichi ^c   Carvalho, Andre Lopes ^a   Jiang, Wei Wen ^a   Park, Hannah Lui ^a   Kim, Myoung Sook ^a   Osada, Motonobu ^a   Mori, Masaki ^b   Sidransky, David ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b KYUSHU UNIVERSITY   (Japan)

^c Saitama Prefectural Cancer Center Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROLASE; PGP9.5; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; LYMPH NODE METASTASIS; MALE; MULTIVARIATE ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN METHYLATION; RESTRICTION MAPPING;

CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DNA METHYLATION; DNA, NEOPLASM; ESOPHAGEAL NEOPLASMS; FEMALE; GENE SILENCING; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROMOTER REGIONS (GENETICS); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 21144442201     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-3923     Document Type: Article

References (25)

1. WHO. The World Health Report. 1997.
2. Pisani P, Parkin D, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999;83:18-29.
3. Stoner G, Rustgi A. Biology of esophageal squamous cell carcinoma. Gastrointest Cancer Biol Diagn Ther 1995;8:141-6.
4. Goseki N, Koike M, Yoshida M. Histolopathologic characterization of early stage esophageal carcinoma. Cancer 1992;69:1088-93.
5. Jones P. DNA methylation and cancer. Oncogene 2002;21:5358-60.
6. Sidransky D. Emerging molecular makers of cancer. Nat Rev Cancer 2002;2:210-9.
7. Yamashita K, Upadhyay S, Osada M. et al. Pharmacological unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell 2002;2:485-95.
8. Tokumaru Y, Yamashita K, Osada M, et al. Inverse correlation between cyclin A1 hypermethylation and p53 mutation in head and neck cancer identified by reversal of epigenetic silencing. Cancer Res 2004;64:5982-7.
9. Wilkinson K. Lee K. Deshpande S. Duerksen-Hughes P, Boss J, Pohl J. The neuron-specific protein PGP9.5 is a ubiquitin carboxy-terminal hydrolase. Science 1989;246:670-3.
10. Liu Y, Fallon L, Lashuel H, Liu Z, Lansbury P Jr. The UCH-L1 gene encodes two opposing enzymatic activities that affect α-synuclein degradation and Parkinson's disease susceptibility. Cell 2002;111:209-18.
11. Tezel E, Hibi K, Nagasaka T, Nakao A. PGP9.5 as a prognostic factor in pancreatic cancer. Clin Cancer Res 2000;6:4764-7.
12. Takase T, Hibi K, Yamazaki T. et al. PGP9.5 overexpression in esophageal squamous cell carcinoma. Hepatogastroenterol 2003;50:1278-80.
13. Sato N, Fukushima N, Maitra A, et al. Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res 2003;63:3735-42.
14. Sugimachi K. Prognostic factors of esophageal carcinoma: univariate and multivariate analysis. J Surg Oncol 1986;31:108-12.
15. Nozoe T, Sugimachi K. Simple staging criteria for esophageal carcinoma. Am J Clin Oncol 2003;26:307-11.
16. Esteller M Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 1999;59:67-70.
17. Kawakami K, Brabender J, Lord RV, et al. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J Natl Cancer Inst 2000;92:1805-11.
18. Sanchez-Cespedes M, Esteller M, Wu L. et al Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res 2000;60:892-5.
19. Jeronimo C, Usadel H, Henrique R, et al. Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J Natl Cancer Inst 2001;93:1747-52.
20. Usadel H, Brabender J, Danenberg KD, et al. Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DIVA of patients with lung cancer. Cancer Res 2002;62:371-5.
21. Brock M, Gou M, Akiyama Y, et al. Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin Cancer Res 2003;9:2912-9.
22. Harada T, Harada C, Wang Y, et al. Role of ubiquitin carboxy terminal hydrolase-L1 in neural cell apoptosis induced by ischemic retinal injury in vivo. Am J Pathol 2004;164:59-64.
23. Ishibashi Y, Takada K. Joh K, Ohkawa K, Aoki T, Matsuda M. Ubiquitin immunoreactivity in human malignant tumors. Br J Cancer 1991;63:320-2.
24. Osada T. Sakamoto M, Mishibori H, et al. Increased ubiquitin immunoreactivity in hepatocellular carcinomas and precancerous lesions of the liver. J Hepatol 1997;26:1266-73.
25. Ishibashi T, Hanyu N, Suzuki Y, et al. Quantitative analysis of free ubiquitin and multi-ubiquitin chain in colorectal cancer. Cancer Lett 2004;211:111-7.